Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02710981
Other study ID # AUH1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 2015
Est. completion date January 2016

Study information

Verified date April 2020
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective self controlled clinical trial. Women with clomiphene Citrate failure, and thin endometrium were recruited (N = 42). In their 6th (Clomiphene citrate only) cycle, women continued on Clomiphene citrate 100 mg/ day for 5 days, and had sonographic measurement of their endometrial thickness , and Doppler evaluation of their uterine arteries on the day of HCG administration. In 7th cycle, women (N = 36) were given usual dose of Clomiphene citrate supplemented with sildenafil vagina gel (5 gm, containing 50 mg sildenafil) twice daily from cycle day 8 till the day of HCG injection. Endometrial thickness and uterine artery Doppler were measured on the day of HCG administration.


Description:

Study design:

This is a prospective self-controlled clinical trial.

Study subjects:

Investigators counseled and recruited 42 infertile women who had been diagnosed with anovulatory infertility, with normal baseline FSH, LH, and free testosterone levels, patent tubes on hysterosalpingography, and normal male semen analysis.

By the time they were enrolled in the study, all women had already completed 5 ovulatory cycles of Clomiphene citrate induction (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) but without conception (clomiphene citrate failure) with thin endometrium (<8mm) in at least 3 cycles. Ovulation was documented sonographically, and with day-21 serum progesterone exceeding 5 ng/ ml in all cases.

Exclusion criteria:

Women with major medical problems, male factor infertility, endocrine abnormalities such as hyperprolactinemia or abnormal thyroid functions, prior ovarian or adnexal surgery, or organic pelvic pathology were not included in the study.

Intervention:

Sixth cycle (Clomiphene citrate only):

Enrolled cases were asked to continue with Clomiphene citrate induction ( at the same dose) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG administration ( when follicular diameter reached 18 mm). Endometrial thickness and Uterine artery Doppler assessment were done in the late proliferative phase ( Day of HCG injection).

Seventh cycle ( Sildenafil vaginal gel and Clomiphene cycle):

Those who didn't conceive on the sixth cycle (41 women) were asked to have an extra (7th) cycle in which they were prescribed the usual dose of Clomiphene citrate in addition to sildenafil vaginal gel. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose. The dose was 5 g gel containing 50 mg sildenafil, applied vaginally twice daily from cycle day 8 to Day of HCG injection. The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.

Evaluation of the study end points:

On day of HCG injection (main follicular diameter of 18 mm) in the 6th, and 7th cycles, women came for follow up and had transvaginal sonographic assessment of their endometrial thickness. Investigators have measured the maximal distance spanning endometrial- myometrial interphase on each endometrial stripe in a sagittal plane in the fundus of the uterus. In addition, Transvaginal Doppler examination was also done on the same visit to evaluate the pulsatility indices of both uterine arteries. When the leading follicle reached 18 mm in diameter, 5000 IU of HCG was prescribed for IM injection.

Although pregnancy rate was not a primary outcome measure in the study, investigators detected pregnancy in 3 cases in the cohort of 36 cases of infertile women with clomiphene failure in which sildenafil gel was added as an adjuvant. Pregnancy was diagnosed with a B-HCG value above 100 mIU/ml, and confirmed later with ultrasound.

Statistics:

Data were analyzed using SPSS program ver. 17 using Student-t-test and Fisher's exact test for comparing data in the 6th and 7th cycles, as appropriate.


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date January 2016
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria:

- Women with clomiphene citrate failure (defined as at least prior 5 ovulatory cycles with clomiphene citrate, with no conception),

- persistently thin endometrium (less than 8 mm in at least 3 cycles).

- normal baseline FSH, LH, and free testosterone levels, patent tubes on hysterosalpingography, and normal male semen analysis

Exclusion Criteria:

- Women with major medical problems,

- male factor infertility,

- endocrine abnormalities such as hyperprolactinemia or abnormal thyroid functions,

- prior ovarian or adnexal surgery, or organic pelvic pathology

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
clomiphene citrate
Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
Sildenafil vaginal gel
In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Outcome

Type Measure Description Time frame Safety issue
Primary Endometrial Thickness Transvaginal sonographic measurement of maximal distance spanning endometrial- myometrial interphase on each endometrial stripe in a sagittal plane in the fundus of the uterus Day of HCG administration
Secondary Uterine Blood Flow Doppler ultrasound is used to measure the pulsatility index in both uterine arteries. Pulsatility index is a measure of the arterial resistance to blood flow. The higher the value of the pulsatility index, the more resistant the uterine arteries are, and hence the worst the outcome. Day of HCG administration
Secondary Clinical Pregnancy Rate Identifying pregnancy through positive urinary HCG test plus sonographic detection of cardiac pulsations At the end of a 28-day menstrual cycle.
See also
  Status Clinical Trial Phase
Completed NCT01653743 - Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women Phase 3
Completed NCT00327366 - Effect of Bright Light on Sex Hormones and Ovulation in Humans N/A
Not yet recruiting NCT02551367 - Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Poly Cystic Ovary Syndrome ( PCOS ) Phase 2
Completed NCT01923194 - Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females Phase 3
Completed NCT01008319 - Traditional Clomiphene Citrate Administration vs. Stair-step Approach Phase 3
Completed NCT00239603 - Efficacy Study of the OV-Watchâ„¢ Personal Fertility Monitor for Women Using Clomiphene Citrate. Phase 4
Recruiting NCT02309047 - The Cycle Disturbances, OLigomenorrhea and Amenorrhea (COLA) Study & Biobank
Completed NCT03252223 - Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS Phase 4
Completed NCT00492882 - Study of Mechanisms of Anovulation in Polycystic Ovary Syndrome Phase 4
Completed NCT02335879 - Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation Phase 3
Completed NCT00471523 - Treatment of Anovulatory Infertility in PCOS Patients Phase 4
Completed NCT02703649 - Administration of Single High Dose Letrozole for Ovulation Induction Phase 4
Completed NCT00213148 - Comparison of Anastrozole Verses Clomiphene Citrate in Stimulating Follicular Growth and Ovulation in Infertile Women With Ovulatory Dysfunction Phase 2
Completed NCT03018314 - Serum Kisspeptin Levels in Infertile Women N/A
Recruiting NCT02186782 - Concomitant CC and E2 Versus CC Alone in Ovulation Induction Phase 4
Not yet recruiting NCT00665171 - Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome N/A
Withdrawn NCT03155828 - Using CPAP to Improve Menstruation in Women With Polycystic Ovarian Syndrome and Obstructive Sleep Apnea
Withdrawn NCT00453219 - FHA: Characterization of Metabolic Status, Brain Circuitry, and Stress-Reactivity N/A
Completed NCT00920634 - Protocol for Drug Use Investigation of Follistim Injection (Study P06132)(COMPLETED)
Recruiting NCT06208995 - Quality of Life in Normogonadotropic Anovulation